Abstract:Objective: To investigate whether the dynamic contrast-enhanced ultrasound (DCE-US) analysis and quantitative parameters could be helpful for predicting histopathologic grades of pancreatic neuroendocrine tumors (pNETs). Methods: This retrospective study conducted a comprehensive review of the CEUS database between March 2017 and November 2021 in Zhongshan Hospital, Fudan University. Ultrasound examinations were performed by an ACUSON Sequioa unit equipped with a 3.5 MHz 6C−1 convex array transducer, and an ACUSON OXANA2 unit equipped with a 3.5 MHz 5C−1 convex array transducer. SonoVue® (Bracco Inc., Milan, Italy) was used for all CEUS examinations. Time intensity curves (TICs) and quantitative parameters of DCE-US were created by Vuebox® software (Bracco, Italy). Inclusion criteria were: patients with histopathologically proved pNETs, patients who underwent pancreatic B-mode ultrasounds (BMUS) and CEUS scans one week before surgery or biopsy and had DCE-US imaging documented for more than 2 min, patients with solid or predominantly solid lesions and patients with definite diagnosis of histopathological grades of pNETs. Based on their prognosis, patients were categorized into two groups: pNETs G1/G2 group and pNETs G3/pNECs group. Results: A total of 42 patients who underwent surgery (n = 38) or biopsy (n = 4) and had histopathologically confirmed pNETs were included. According to the WHO 2019 criteria, all pNETs were classified into grade 1 (G1, n = 10), grade 2 (G2, n = 21), or grade 3 (G3)/pancreatic neuroendocrine carcinomas (pNECs) (n = 11), based on the Ki−67 proliferation index and the mitotic activity. The majority of the TICs (27/31) of pNETs G1/G2 were above or equal to those of pancreatic parenchyma in the arterial phase, but most (7/11) pNETs G3/pNECs had TICs below those of pancreatic parenchyma from arterial phase to late phase (p < 0.05). Among all the CEUS quantitative parameters of DCE-US, values of relative rise time (rPE), relative mean transit time (rmTT) and relative area under the curve (rAUC) were significantly higher in pNETs G1/G2 group than those in pNETs G3/pNECs group (p < 0.05). Taking an rPE below 1.09 as the optimal cut-off value, the sensitivity, specificity and accuracy for prediction of pNETs G3/pNECs from G1/G2 were 90.91% [58.70% to 99.80%], 67.64% [48.61% to 83.32%] and 85.78% [74.14% to 97.42%], respectively. Taking rAUC below 0.855 as the optimal cut-off value, the sensitivity, specificity and accuracy for prediction of pNETs G3/pNECs from G1/G2 were 90.91% [66.26% to 99.53%], 83.87% [67.37% to 92.91%] and 94.72% [88.30% to 100.00%], respectively. Conclusions: Dynamic contrast-enhanced ultrasound analysis might be helpful for predicting the pathological grades of pNETs. Among all quantitative parameters, rPE, rmTT and rAUC are potentially useful parameters for predicting G3/pNECs with aggressive behavior.

Using percutaneous computed tomography-guided core needle biopsy of liver metastases from gastroenteropancreatic neuroendocrine tumors to identify inter-tumor grading classification heterogeneity

Machine Learning Methods Based on CT Features Differentiate G1/G2 from G3 Pancreatic Neuroendocrine Tumors.

Clinical Analysis of Gastroenteropancreatic Neuroendocrine Tumor with Liver Metastasis, Compared with Primary Hepatic Neuroendocrine Tumor.

Percutaneous computed tomography-guided core needle biopsy can be used to histologically confirm the clinical features and long-term prognosis of pulmonary neuroendocrine neoplasms

[Study on Clinicopathologic Grading System and Prognosis of Primary Hepatic Neuroendocrine Neoplasms].

Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors

Utility of CT in Differentiating Liver Metastases of Well-Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms from Poorly-Differentiated Neuroendocrine Neoplasms

Risk Factors Affecting Prognosis in Metachronous Liver Metastases from WHO Classification G1 and G2 Gastroenteropancreatic Neuroendocrine Tumors after Initial R0 Surgical Resection

Differentiating Hepatic Metastases Of Gastroenteropancreatic Neuroendocrine Cancer And Adenocarcinoma Using Enhanced Ct

Retrospective Analysis of Interventional Treatment of Hepatic Metastasis from Gastroenteropancreatic Neuroendocrine Tumors.

Dynamic Enhanced CT: is There a Difference Between Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumor and Adenocarcinoma

Clinicopathological correlations in 38 cases of gastroenteropancreatic high-grade neuroendocrine neoplasms

A Real-Life Treatment Cohort of Pancreatic Neuroendocrine Tumors: High-grade Increase in Metastases Confers Poor Survival

MRI features and pathological grading of hepatic neuroendocrine neoplasm

Efficacy of first-line chemotherapy based on primary site of tumor versus etoposide-platinum in advanced gastroenteropancreatic neuroendocrine carcinoma

The Prognostic Value of Multidetector CT Features in Predicting Overall Survival Outcomes in Patients with Pancreatic Neuroendocrine Tumors.

Prediction of Pathological Grades of Pancreatic Neuroendocrine Tumors Based on Dynamic Contrast-Enhanced Ultrasound Quantitative Analysis

Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center.

Clinical Relevance of Different WHO Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology

Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms

Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-Dotatate and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms